Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 3 1Phase 1 1

Status

Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 19Triple Negative Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Brain Neoplasms 3Salivary Gland Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Urothelial Cancer 1Laryngeal Neoplasms 1Klatskin Tumor 1Hypopharyngeal Neoplasms 1HER2-negative Breast Cancer 1Glioblastoma 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × sacituzumab govitecan × Clear all
NCT05581589 2026-04-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

University of Washington

Phase 2 Terminated
4 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms

NCT05327530 2026-04-24

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

EMD Serono

Phase 2 Active not recruiting
256 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06528483 2024-07-30

preSAVE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Not yet recruiting
63 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡